Mukhtar Shah, MD
Psychiatry · Wichita, KSNPI 1396763827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 692 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,318 and has fallen 62.7% since, to $864 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Vanda Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$757
- Neurocrine Biosciences, Inc.$657
- plus $6K from 24 others
What the payments were for
- Food & beverage$11,65598%
- Education$1932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 68 | $1,284 |
| Vanda Pharmaceuticals Inc. | 55 | $1,203 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,171 |
| Teva Pharmaceuticals USA, Inc. | 56 | $1,046 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $757 |
| Neurocrine Biosciences, Inc. | 60 | $657 |
| Alkermes, Inc. | 31 | $624 |
| AbbVie(2 entities) | 38 | $608 |
| Sunovion Pharmaceuticals Inc. | 44 | $581 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $539 |
| Neos Therapeutics, LP | 41 | $521 |
| Ironshore Pharmaceuticals Inc. | 6 | $372 |
| Eisai Inc. | 30 | $367 |
| Supernus Pharmaceuticals, Inc. | 17 | $323 |
| Bausch Health US, LLC | 20 | $281 |
| Merck | 18 | $274 |
| Johnson & Johnson | 15 | $270 |
| Axsome Therapeutics, Inc. | 12 | $256 |
| Idorsia Pharmaceuticals US Inc | 12 | $195 |
| Avanir Pharmaceuticals, Inc. | 7 | $105 |
| Shire North American Group Inc | 6 | $92 |
| Corium, LLC | 4 | $88 |
| Almatica Pharma LLC | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $46 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Alfasigma USA, Inc. | 2 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $24 |
| Biogen | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,848 in reported general payments places this provider in the 90th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 16 | $34,155 |
| QuviviqDaridorexant Hcl | 15 | $6,378 |
| Perphenazine | 37 | $2,304 |
| Quetiapine Fumarate | 184 | $2,216 |
| Alprazolam | 278 | $2,084 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $1,967 |
| Bupropion XlBupropion Hcl | 133 | $1,939 |
| Duloxetine Hcl | 115 | $1,921 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 179 | $1,910 |
| Clozapine | 21 | $1,898 |
| Desipramine Hcl | 13 | $1,841 |
| Buspirone Hcl | 123 | $1,664 |
| Olanzapine | 80 | $1,559 |
| Lorazepam | 123 | $1,260 |
| Trazodone Hcl | 213 | $1,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,171 | $34,15516 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $195 | $6,37815 claims |
| Almatica Pharma LLCSertraline Hcl | $56 | $1,053197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Wichita
- Sheldon PreskornWichita$498K
- Heidi OgdenWichita$55K
- Ralph BharatiWichita$26K
- Paul MurphyWichita$19K
- Dwight St ClairWichita$18K
- Rex LearWichita$11K
- Lin XuWichita$9K
- Mercedes PeralesWichita$8K
- Jasmine KaurWichita$6K
- Peter SeilerWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.